Business The science behind a fond farewell Published 3 years ago on 7 October 2021 By Terry Power Between the high cost and testing hurdles, molnupiravir may not be the “game changer” against COVID. Read More Related Topics:biogen aduhelmcoronavirusCOVIDcovid treatment costsdigital healthfarewellfondfortune the capsuleGE Healthcaremonoclonal antibodiessciencethe capsulethe science of a farewell